Publication:
Dendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2

Simple item page
dc.contributor.authorLázaro‐Gorines, Rodrigo
dc.contributor.authorPérez, Patricia
dc.contributor.authorHeras‐Murillo, Ignacio
dc.contributor.authorAdán‐Barrientos, Irene
dc.contributor.authorAlbericio, Guillermo
dc.contributor.authorAstorgano, David
dc.contributor.authorFlores, Sara
dc.contributor.authorLuczkowiak, Joanna
dc.contributor.authorLabiod, Nuria
dc.contributor.authorHarwood, Seandean L.
dc.contributor.authorSegura‐Tudela, Alejandro
dc.contributor.authorRubio‐Pérez, Laura
dc.contributor.authorNugraha, Yudhi
dc.contributor.authorShang, Xiaoran
dc.contributor.authorLi, Yuxing
dc.contributor.authorAlfonso, Carlos
dc.contributor.authorAdipietro, Kaylin A.
dc.contributor.authorAbeyawardhane, Dinendra L.
dc.contributor.authorNavarro, Rocío
dc.contributor.authorCompte, Marta
dc.contributor.authorYu, Wenbo
dc.contributor.authorMacKerell, Alexander D.
dc.contributor.authorSanz, Laura
dc.contributor.authorWeber, David J.
dc.contributor.authorBlanco, Francisco J.
dc.contributor.authorEsteban, Mariano
dc.contributor.authorPozharski, Edwin
dc.contributor.authorGodoy‐Ruiz, Raquel
dc.contributor.authorMuñoz, Inés G.
dc.contributor.authorDelgado, Rafael
dc.contributor.authorSancho, David
dc.contributor.authorGarcía‐Arriaza, Juan
dc.contributor.authorÁlvarez‐Vallina, Luis
dc.date.accessioned2023-11-21T11:12:38Z
dc.date.available2023-11-21T11:12:38Z
dc.date.issued2023
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipSARS-CoV-2 B.1.351 and B.1.167.2 viruses used in this study were obtained through the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 653316. SARS-CoV-2 B.1 (MAD6 isolate) was kindly provided by José M. Honrubia and Luis Enjuanes (CNB-CSIC, Madrid, Spain). The authors thank Centro de Investigación en Sanidad Animal (CISA)-Instituto Nacional de Investigaciones Agrarias (INIA-CSIC) (Valdeolmos, Madrid, Spain) for the BSL-3 facilities. Research in LAV laboratory was funded by the BBVA Foundation (Ayudas Fundación BBVA a Equipos de Investigación Científica SARS-CoV-2 y COVID19); the MCIN/AEI/10.13039/501100011033 (PID2020-117323RB-I00 and PDC2021-121711-I00), partially supported by the European Regional Development Fund (ERDF); the Carlos III Health Institute (ISCIII) (DTS20/00089), partially supported by the ERDF, the Spanish Association Against Cancer (AECC 19084); the CRIS Cancer Foundation (FCRISIFI-2018 and FCRIS-2021-0090), the Fundación Caixa-Health Research (HR21-00761 project IL7R_LungCan), and the Comunidad de Madrid (P2022/BMD-7225 NEXT_GEN_CART_MAD-CM). Work in the DS laboratory was funded by the CNIC; the European Union’s Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator Grant 725091; MCIN/AEI/10.13039/501100011033 (PID2019-108157RB); Comunidad de Madrid (B2017/BMD-3733 Immunothercan-CM); Atresmedia (Constantes y Vitales prize); Fondo Solidario Juntos (Banco Santander); and “La Caixa” Foundation (LCF/PR/HR20/00075). The CNIC was supported by the ISCIII, the MCIN and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020- 001041-S funded by MCIN/AEI/10.13039/501100011033). Research in RD laboratory was supported by the ISCIII (PI2100989) and CIBERINFEC; the European Commission Horizon 2020 Framework Programme (grant numbers 731868 project VIRUSCAN FETPROACT-2016, and 101046084 project EPIC-CROWN-2); and the Fundación CaixaHealth Research (grant number HR18-00469 project StopEbola). Research in CNB-CSIC laboratory was funded by Fondo Supera COVID19 (Crue Universidades-Banco Santander) grant, CIBERINFEC, and Spanish Research Council (CSIC) grant 202120E079 (to J.G.-A.), CSIC grant 2020E84 (to M.E.), MCIN/AEI/10.13039/501100011033 (PID2020- 114481RB-I00 to J.G-A. and M.E.), and by the European CommissionNextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) to J.G.-A. and M.E. Work in the CIB-CSIC laboratory was supported by MCIN/AEI/10.13039/501100011033 (PID2019-104544GB-I00 and 2023AEP105 to CA, and PID2020-113225GB-I00 to F.J.B.). Cryo-EM data were collected at the Maryland Center for Advanced Molecular Analyses which was supported by MPOWER (The University of Maryland Strategic Partnership). I.H.-M. receives the support of a fellowship from la Caixa Foundation (ID 100010434, fellowship code: LCF/BQ/IN17/11620074) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 71367. L.R.-P. was supported by a predoctoral fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck.es_ES
dc.identifier.citationAdv Sci (Weinh). 2023 Oct 20:e2304818.es_ES
dc.identifier.doi10.1002/advs.202304818es_ES
dc.identifier.e-issn2198-3844es_ES
dc.identifier.issn2198-3844es_ES
dc.identifier.journalAdvanced Sciencees_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16702
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Inmunobiologíaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleDendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationb7906213-cb71-44fd-91a9-24c163b79dfa
relation.isAuthorOfPublication58aa2591-8084-4500-bfe4-8f2c54e398e9
relation.isAuthorOfPublication.latestForDiscoveryb7906213-cb71-44fd-91a9-24c163b79dfa

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dendritic Cell_Mediated_Adv Sci_2023.pdf
Size:
2.47 MB
Format:
Adobe Portable Document Format
Description:
Artículo
Download

Collections

Grupos de investigación